{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 47,
  "pageCount": 54,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes clinical trial data and comparative pharmacokinetic data against oral tamoxifen.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/47",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "This exploratory study in four postmenopausal women diagnosed with VVA demonstrated that a self-administered vaginal suppository containing tamoxifen (20mg) dosed daily for one week and twice weekly for three months was effective in reducing vaginal pH and vaginal dryness.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "480433e1-72c7-42b2-abdc-cabeccd761b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.66
      },
      "kind": "paragraph",
      "text": "In addition, systemic absorption of tamoxifen was not significant: After 8 weeks of study treatment with vaginal tamoxifen, median plasma concentration of tamoxifen was 5.8 ng/ml. In comparison, oral tamoxifen average is 122 ng/ml.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5099cf2f-c2f3-444a-b94e-d859725a8658",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.02,
        "y": 0.81
      },
      "kind": "source-note",
      "text": "1. Clin. Exp. Obstet. Gynecol. 2. medicalnewstoday.com 3. US Food and Drug Administration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "717fe05e-490f-4c2f-9191-70ef5c843580",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.78,
        "x": 0.11,
        "y": 0.34
      },
      "kind": "table",
      "text": "Vaginal Tamoxifen, Enrollment (Baseline), On Treatment (Month 3), Paired Difference (Baseline vs. Month 3), Median Vaginal pH, 7.1, 5.0, -2.0 median, Vaginal Dryness, 8.0, 3.0, -5.5 median",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a749259-93d4-42f6-b493-00f4a0d309a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.36,
        "x": 0.32,
        "y": 0.16
      },
      "kind": "title",
      "text": "DARE-VVA1 - Proof of Concept",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4782f14a-f179-439d-8771-79b383de1472",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}